NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Zoetis Inc is a large cap company (market value between $10 billion and $200 billion) in the Drug Manufacturers - Specialty & Generic industry.
Zoetis discovers, develops, manufactures and commercializes therapeutic products for animal health, encompassing vaccines, diagnostics, biodevices and genetic testing solutions. The company operates across two segments: the United States and International markets, serving companion animal and livestock customers through diverse offerings spanning parasitic control, immunization, dermatological treatments, anti-infective agents, pain management and laboratory diagnostics.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Zoetis Inc stock.
Undervalued: intrinsic value $113.50 per share, market price $79.59, margin of safety 29.9% (as of 2026-10-19).
Discounting its cash flows at 8.1% (average of 3 methods) values the shares at $113.50; the price of $79.59 is 30% below that value, and 79% of that value comes from beyond year five.
Leak Score: 81/100 on 11 of 12 signals (Strong Leak).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
5 more in this industry show a wider margin of safety.
ZTS is undervalued (as of the 2026-10-19 close). Discounting its cash flows at 8.1% (average of 3 methods) values the shares at $113.50; the price of $79.59 is 30% below that value, and 79% of that value comes from beyond year five.
$113.50 per share (as of the 2026-10-19 close), against a market price of $79.59. That is a margin of safety of 29.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
81 out of 100, which we rate "Strong Leak", on 11 of 12 value investing signals.